Literature DB >> 7585980

Evidence for protein tyrosine kinase involvement in CD6-induced T cell proliferation.

L M Osorio1, C Ordonez, C A Garcia, M Jondal, S C Chow.   

Abstract

Several studies have demonstrated that addition of soluble anti-CD6 mAbs to 12-O-tetradecanoylphorbol 13-acetate (TPA)-treated naive T cells can induce cell proliferation. We showed in the present study that cell proliferation in TPA-treated T cell cultures can be enhanced several fold when the anti-CD6 mAbs are either immobilized or crosslinked with rabbit anti-mouse immunoglobulins (RAM Ig). Using a src family protein tyrosine kinase (PTK) inhibitor, herbimycin A, the cell proliferation induced by the anti-CD6 mAb, IOR-T1, in TPA-treated T cells were effectively abolished. Analysis of the cellular proteins in these cells after crosslinking the CD6 receptor with IOR-T1 (followed by RAM Ig) in the presence of TPA resulted in an increased level of tyrosine phosphorylation. Pretreatment of native T cells with herbimycin A (0.5 and 1 microgram/ml) for 18 hr completely inhibited the tyrosine phosphorylation on cellular substrates in T cell cultures stimulated with IOR-T1/RAM Ig and TPA. Similar concentrations of herbimycin A also inhibited the increase in IL-2 mRNA expression and cell proliferation in T cell cultures after IOR-T1/RAM Ig and TPA treatment. Furthermore, the increase in cytosolic free Ca2+ concentration in naive T cells after crosslinking of the CD6 receptor with IOR-T1/RAM Ig was also inhibited by herbimycin A. Taken together, our results suggest that CD6-mediated T cell proliferation is IL-2 dependent, and involves tyrosine kinase activity which is strictly dependent on protein kinase C activation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7585980     DOI: 10.1006/cimm.1995.0006

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  7 in total

1.  CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction.

Authors:  P Nair; R Melarkode; D Rajkumar; E Montero
Journal:  Clin Exp Immunol       Date:  2010-08-19       Impact factor: 4.330

Review 2.  Apoptosis in B-chronic lymphocytic leukaemia.

Authors:  L M Osorio; M Aguilar-Santelises
Journal:  Med Oncol       Date:  1998-12       Impact factor: 3.064

3.  The role of CD6 in autoimmune diseases.

Authors:  David A Fox
Journal:  Cell Mol Immunol       Date:  2018-03-23       Impact factor: 11.530

4.  Role of the CD6 glycoprotein in antigen-specific and autoreactive responses of cloned human T lymphocytes.

Authors:  N G Singer; B C Richardson; D Powers; F Hooper; F Lialios; J Endres; C M Bott; D A Fox
Journal:  Immunology       Date:  1996-08       Impact factor: 7.397

5.  Attenuation of Murine Collagen-Induced Arthritis by Targeting CD6.

Authors:  Yan Li; Jeffrey H Ruth; Stephanie M Rasmussen; Kalana S Athukorala; Daniel P Weber; M Asif Amin; Phillip L Campbell; Nora G Singer; David A Fox; Feng Lin
Journal:  Arthritis Rheumatol       Date:  2020-08-14       Impact factor: 10.995

6.  Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases.

Authors:  Ruby Alonso-Ramirez; Séverine Loisel; Caroline Buors; Jacques-Olivier Pers; Enrique Montero; Pierre Youinou; Yves Renaudineau
Journal:  Arthritis       Date:  2011-02-10

7.  Biophysical Characterization of CD6-TCR/CD3 Interplay in T Cells.

Authors:  Marjolein B M Meddens; Svenja F B Mennens; F Burcu Celikkol; Joost Te Riet; Johannes S Kanger; Ben Joosten; J Joris Witsenburg; Roland Brock; Carl G Figdor; Alessandra Cambi
Journal:  Front Immunol       Date:  2018-10-09       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.